Health officials are issuing warnings about the potential for addiction and rebound congestion from prolonged use of over-the-counter nasal decongestant sprays.

Rebound Congestion and Addiction Risks

British health authorities are cautioning the public about the risks associated with using nasal decongestant sprays, such as Vicks, Sudafed, and Otrivine, for extended periods. These sprays, containing xylometazoline and oxymetazoline, provide temporary relief by reducing swelling in nasal passages.

However, the Medicines and Healthcare products Regulatory Agency (MHRA) warns that using these sprays for more than five consecutive days can lead to dependency, known as rebound congestion or rhinitis medicamentosa. This occurs when the nasal tissues become reliant on the medication.

Symptoms and Potential Complications

Rebound congestion can manifest as persistent irritation, a runny nose, sneezing, and continued blockage. In severe cases, chronic swelling can lead to breathing difficulties and even facial disfigurement, potentially requiring surgical intervention.

MHRA Guidance and Public Awareness

The MHRA is urging consumers to adhere to the five-day usage limit and plans to update product packaging and leaflets to reflect this guidance. Professor Amira Guirguis of the Royal College of Pharmacy supports clearer product information and public messaging to raise awareness.

Recent studies reveal a significant lack of public awareness, with nearly 60% of pharmacists believing patients are unaware of the long-term risks. Over 20% of adults admit to using the sprays for longer than a week.

Personal Stories Highlight the Issue

Charlotte Johnstone, a 30-year-old, has shared her experience battling a 23-year addiction to nasal decongestant sprays, which began at age seven. Her story illustrates the psychological and physical toll of prolonged use, including anxiety, sleep disturbances, and a diminished sense of smell.

While most individuals can discontinue use without lasting damage, some may require steroid-based treatments to manage withdrawal symptoms. The MHRA advises consulting a healthcare professional if congestion persists beyond five days.